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Abstract
Background: Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women of reproductive
age. The study was commenced to assess the favorable effects of Rutin against metabolic, biochemical, histological,
and androgenic aspects of polycystic ovary syndrome in rats.
Methods: Female Sprague-Dawley rats were administered letrozole (1 mg/kg) per orally (p.o) for a period of
21 days for the induction of PCOS, followed by dose of rutin (100 mg/kg and 150 mg/kg, p.o) for 15 days using 0.
5% w/v CMC as vehicle. Metformin was also given as a standard control to one of the rat groups.
Serum estradiol, progesterone, testosterone, serum lipid parameters, CRP and glucose levels were evaluated.
Furthermore, antioxidant activity was tested using superoxide dismutase, catalase, glutathione per-oxidase and
reactive-oxygen species level.
Results: Rutin flavonoid had a dose-dependent effect on androgenic levels depicting more recovery in the rutin-I treated
group, while rutin-II treated groups showed better antioxidant and lipid profiles as compared with PCOS groups. A decrease
in the value of C reactive protein (CRP) and a restoration in the proportion of estrous phase smears were observed in the rutin
treated groups. Histopathological examination of ovary revealed a significant decrease in the number of cystic follicles in post
treated groups. The effects observed with rutin were moderately similar to that with standard metformin, a widely used
treatment drug for PCOS.
Conclusion: The study provides evidence for the potential ameliorative effects of rutin against clinical and biochemical
features of PCOS.
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Background
Polycystic ovary syndrome (PCOS) is the most prevalent
endocrinopathy in women of reproductive age. PCOS
are distinguished by hyperandrogenism showing symp-
toms of hirsutism, acne, androgenic alopecia; irregularities
of menstrual cycle such as polymenorrhea, oestrogen-
replete amenorrhoea, metrorrhagia and oligomenorrhea,
dyslipidemia, insulin resistance, chronic anovulation,
hormonal imbalances and reduced fertility [1–4].
Various metabolic and clinical complications are asso-
ciated with PCOS such as impaired glucose tolerance
and diabetes, extensive coronary artery disease, hyper-
tension, chronic oligo-ovulation, anovulation, infertility,
endometrial, ovarian and breast cancers [5–11].
PCOS patients usually have a high oxidative profile
which causes disturbance in antioxidants balance, lead-
ing to harmful effects of reactive oxygen species (ROS)
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including infertility, endometriosis, abortion, birth de-
fects, preeclampsia, injury to ovarian epithelium’s DNA,
excessive apoptosis and alteration in cell signalling
process [12, 13].
Letrozole, known as Femara, inhibits the cytochrome
P450 enzyme, aromatase, by the catalytic action of which
estrogen is synthesized by the androgens. The absence
of aromatase enzyme causes disturbance in the steroido-
genesis, thus causing increase in the production of
androgens developing PCOS [14].
Metformin is commonly known as Glucophage and it be-
longs to the biguanide class of drugs. It has the chemical
formula of C4H11N5 and molecular weight of 129.1636 g/
mol. Metformin suppresses the process of gluconeogenesis
and results in the decrease in blood sugar levels, reduce
body weight and may improve the fibrinolysis activity, lipid
profile, insulin sensitivity and glucose uptake and utilization
in peripheral tissues of skeletal muscle and adipocytes [15].
Metformin is also a best drug for PCOS treatment [16].
Flavonoids were chosen as a drug of choice for the
cure of antiandrogenic, hyperlipidemic, hyperglycemic
and oxidative stress consequences of PCOS. Flavonoids
show a variety of biological actions including antimicro-
bial, antiviral, antiulcerogenic, cytotoxic, antineoplastic,
anti-inflammatory, antioxidant, antihypertensive, hepato-
protective, hypolipidemic and antiplatelet activities [17].
The natural rutin (3′,4′,5,7-tetrahydroxyflavone-3-ruti-
noside) is one of the important phytochemicals. Rutin is
a bioflavonoid which is necessary for the absorption of
vitamin C and acts as an anti-oxidizer [18]. Rutin has a
noteworthy range of scavenging characteristics on oxi-
dizing species such as hydroxy radical, superoxide rad-
ical, and peroxyl radical by donating hydrogen atoms to
peroxy radicals, superoxide anions, and singlet oxygen
and hydroxyl radicals, it also functions as a terminator
and chelator of metal ions that are able of oxidizing lipid
peroxidation [19–21].
In this study, PCOS was induced by the use of aroma-
tase inhibitor, letrozole, in the rodent model. Rutin was
selected to be used as a therapy against polycystic ovary
syndrome in the present study. Its comparative effects
with metformin were assessed and it is anticipated to
recover the complications caused due to PCOS.
The present study was designed to scrutinize whether
rutin is effective in treating the endocrine, oxidative and
reproductive dysfunctions in letrozole induced PCOS and
to assess the prognostic power of this flavonoid in improv-
ing the clinical and biochemical features of PCOS.
Methods
Experimental animals
Six weeks old female Sprague-Dawley rats (Rattus norvegi-
cus), having weight of about 155 ± 10 g and exhibiting nor-
mal estrous cycle of 6 days were taken from Animal house
of Quaid-i-Azam University, Islamabad. Animals were
supplied with pellets of feed and drinking water ad libi-
tum and maintained in controlled experimental conditions
in stainless steel cages. They were subjected to a 12:12 h
light/dark cycles (relative humidity 60–65%) with room
temperature of about 20 ± 5 °C for a period of 36 days.
Animal handling, treatments and scarification was ap-
proved by the ethical committee of Department of Animal
Sciences Quaid-i-Azam University, Islamabad.
PCOS was induced by oral administration of aromatase
inhibitor, letrozole (1 mg/kg) dissolved in 0.5% CMC (2 mg/
kg) for 21 days. This dose was selected using the previous
studies of Kafali et al. [22] and Rezvanfar et al. [23]. During
the experiment, the estrous cycle phases were monitored by
the analyses of relative proportion of leukocytes, epithelial
and cornified cells. All rats were randomly divided into fol-
lowing five groups consisting of five rats in each group: (i)
control group (CMC; 2 mg/kg/day, p.o.), (ii) PCOS group
(letrozole; 01 mg/kg/day, p.o.), (iii) Metformin group (met-
formin; 2 mg/100 g/day, p.o.), (iv) Rutin-I group (rutin;
100 mg/kg/day, p.o.), and (v) Rutin-II group (rutin; 150 mg/
kg/day, p.o.). Letrozole and CMC were administered for
36 days while metformin and the two rutin doses were ad-
ministered from day 21 to the day 36 of the experiment.
Rats were sacrificed on 37th day, 24 h later the termin-
ation of the experiment. Blood was collected from the
aorta of the rats under anesthesia in heparinized syringes
and kept at -20 °C. It was then centrifuged at 3000 rpm
for 15 min. Blood plasma was separated for biochemical
and hormonal analysis and ovaries were taken out for
histopathological and antioxidant assessments.
Assessment of experimentally induced PCOS
Anthropometrical parameters
Changes in body weight were recorded every week in
control, PCOS, metformin and rutin treated groups
throughout the experiment.
Weight gain, body length, body mass index (BMI), the
abdominal circumference to thoracic circumference (AC/
TC) ratio, Lee index and specific rate of body mass gain
were determined during the day of dissection using stand-
ard measurement methods.
Ovarian weight, diameter and ovarian organ index
were also evaluated using usual measurement procedures.
From the first day of study until termination, every morn-
ing colypocytological examination was performed to check
estrous cyclicity in rats.
Biochemical analysis
The concentration of blood glucose was evaluated on day
1, 21 and 36 of experiment using Accu Chek glucometer.
Antioxidant enzymes and protein levels were esti-
mated in ovarian tissue of control and treated animals.
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ROS value was determined using the protocol used by
Hayashi et al. [24]. Catalase (CAT), Guaiacol peroxidase
(POD) levels were analyzed as described in Chance and
Maehly [25] with some modifications. Superoxide dismut-
ase (SOD) was assessed by the protocol adopted by Kakkar
et al. [26] and Thiobarbituric reactive acid substances
(TBARS) levels were measured using Wright et al. [27]
method. Gluthathione reductase (GSR); Carlberg & Man-
nervik [28], Glutathione-S-transferase (GST); Habig et al.
[29], reduced Glutathione (GSH); Tietze et al. [30], Gluta-
thione peroxidase (GSH-px); Mohandas et al. [31] and
lipid hydroperoxide (LOOH) levels were measured using
standard protocols used by (Jiang et al. [32]) on Smart
Spec TM plus spectrophotometer.
Total cholesterol (TC), Triglycerides (TG), High-
density lipoprotein (HDL-C), total protein and CRP
were analyzed using commercially available kits of
AMP diagnostics AMEDA Labordiagnostik GmbH,
Austria. All the procedures were carried out using the
manufacturer’s instructions.
Very low-density lipoprotein cholesterol (VLDL-C)
and low density lipoprotein cholesterol (LDL-C) were
calculated using Friedewald’s formula. Non-HDL choles-
terol (non-HDL-C) was calculated as the difference
between TC and HDL-C while TC/HDL, TG/HDL and
LDL/HDL were also assessed.
Hormonal analysis
Serum total testosterone, progesterone and estradiol
were evaluated using commercially available ELISA kits
of Microlisa AMGENIX Int, Inc. USA. All the proce-
dures were carried out using manual instructions.
Histopathological analysis
The ovaries were processed for paraffin embedding, sec-
tioned at 7 μm, stained with hematoxylin and eosin, and
observed under microscope at 100 × s magnification. All
the ovarian follicles were examined depending upon
their granulosa and morphology. The presence or absence
of corpus luteum and thickness of peripheral theca and
granulosa layer were also observed.
Statistical analysis
Data were represented as Mean ± Standard Error of
Mean (SEM). Graph Pad PRISM 5 (San Diego, CA,
USA) was used to describe the results statistically. Com-
parison of mean was done by using one-way analysis of
variance (ANOVA), followed by Tukey test.
Results
Effect of metformin and rutin on anthropometrical
parameters
Administartion of letrozole to female rats for 36 days
resulted in a significant increase in final body weights of
PCOS group as compared to control (P < 0.05), however
all the other anthropometrical parameters including
weight gain, AC, TC, AC/TC ratio, BMI, Lee index and
specific rate of body mass gain remained non-significant
among rats in the various groups. Body length showed a
significant increase in the PCOS group as compared to
control group (P < 0.05) (Table 1).
Effect of metformin and rutin on colpocytological
examination
Administration of letrozole to rats for 36 days caused
disturbance of normal estrous cycle starting from day 17th
till the end, in the PCOS group, resulting into a profuse
vaginal secretion. Mainly diestrus stage remained domin-
ant in it, exhibiting irregularity of the estrous cycle as
compared to control group. In rats treated with metfor-
min, rutin (100 mg/kg) and rutin (150 mg/kg), the normal
Table 1 Effect of Rutin-I (100 mg/kg) and Rutin-II (150 mg/kg) on anthropometrical parameters in Letrozole induced PCOS rats after
36 days of experiment
Parameters Control PCOS Metformin Rutin-I Rutin-II
Weight gain (g) 25.20 ± 3.32 62.00 ± 10.61 46.20 ± 8.73 52.40 ± 5.16 36.01 ± 15.72
AC 14.78 ± 0.42 15.82 ± 0.27 15.74 ± 0.29 15.2 ± 0.34 15.02 ± 0.29
TC 13.86 ± 0.27 14.94 ± 0.18 14.78 ± 0.29 14.92 ± 0.18 14.36 ± 0.15
AC/TC ratio 1.06 ± 0.02 1.05 ± 0.01 1.06 ± 0.01 1.01 ± 0.01 1.04 ± 0.02
Body Length (cm) 19.24 ± 0.35 20.62 ± 0.36a* 20.42 ± 0.29 20.50 ± 0.27 20.12 ± 0.28
Body mass Index (g/cm2) 0.491 ± 0.016 0.545 ± 0.023 0.477 ± 0.018 0.522 ± 0.025 0.493 ± 0.029
Lee Index 0.294 ± 0.004 0.292 ± 0.006 0.288 ± 0.003 0.293 ± 0.005 0.287 ± 0.004
Specific Rate of Body mass gain (g/kg) 4.343 ± 0.945 27.760 ± 8.616 16.211 ± 5.041 26.660 ± 5.475 16.170 ± 9.213
AC/TC, abdominal circumference to thoracic circumference; PCOS, polycystic ovary sundrome
Values are expressed as Mean ± SEM
*p< 0.05
aValue vs control
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estrous cycle depicted a restoration of regular phases
when compared with control and PCOS groups.
Effect of metformin and rutin on weights of ovaries
There was no significant difference noted in weights,
diameter and ovarian organ index among the different
groups (Table 2).
Effect of metformin and rutin on glucose concentration
On the initial day of experiment blood glucose levels
were measured. Mean ± SEM is given in Table 3. There
was no major change in the mean values among the
groups on the initiation of PCOS induction. On day 21,
before the start of post treatment, glucose levels were
again measured. PCOS and metformin group depicted
significant increase (P < 0.001) when compared with con-
trol group, whereas, rutin–I and rutin–II groups illus-
trated significant increase (P < 0.05) as compared to
control group. On the termination of experiment i.e., on
day 36, highly significant increase (P < 0.001) in glucose
concentration was noticed in PCOS group as compared to
control group. On contrary to this, the metformin, rutin-I
(100 mg/kg) and rutin-II (150 mg/kg) post treated groups
showed highly significant decrease (P < 0.001) when com-
pared with PCOS group.
Effect of metformin and rutin on total protein and C
reactive protein
In PCOS group, the total protein values increased sig-
nificantly as compared with the control group (P < 0.05)
while they were significantly reduced in the rutin-II
group (P < 0.05) when compared with PCOS group.
The values of C-reactive protein (CRP) increased sig-
nificantly (P < 0.05) in the PCOS group when compared
with the control group. None of the other groups i.e.,
metformin, rutin-I (100 mg/kg) and rutin-II (150 mg/
kg) exhibited any significant change in the CRP values
when compared with control, PCOS and among them-
selves (Table 4).
Effect of metformin and rutin on ROS
The value of ROS in PCOS group increased significantly
as compared to that of control group (P < 0.05) but the
change was not significant when taken into comparison
with metformin and rutin groups. The values of metfor-
min, rutin-I and rutin-II groups varied significantly as
compared with that of the PCOS group (P < 0.05). But
there was non-significant change in metformin, rutin-I
and rutin-II groups as compared with that of the control
group and also among each other (Table 5).
Effect of metformin and rutin on antioxidant profile
The results regarding the protective effects of rutin
against PCOS in rat ovaries and activities of antioxidant
enzymes such as CAT, POD, SOD, TBARS, LOOH,
GSH-Px, GSR, GSH and GST are shown in Table 5. Ac-
tivities of antioxidant enzymes such as CAT, POD, SOD,
GSR, GST, GSH and GSH-Px were significantly reduced
in PCOS group as compared to control group. This re-
duction in enzymes activity was reversed non signifi-
cantly by the treatment of metformin while significant
increase was seen in the values of SOD, GSR and GSH
(P < 0.05). Rutin (100 mg/kg) did not show any signifi-
cant difference (P < 0.05) among various groups except
the significant increase in the SOD and GSH value as
Table 2 Effect of Rutin-I (100 mg/kg) and Rutin-II (150 mg/kg) on weights, diameter and ovarian organ index of ovaries in Letrozole
induced PCOS rats after 36 days of experiment
Groups (n=5) Control PCOS Metformin Rutin-I Rutin-II
Weight of left ovary (mg) 57.03 ± 3.23 66.67 ± 4.53 57.67 ± 5.08 66.33 ± 2.54 61.44 ± 4.23
Weight of right ovary (mg) 56.01 ± 2.44 65.25 ± 5.09 59.20 ± 4.01 64.03 ± 6.78 60.41 ± 3.72
Diameter of right ovary (mm) 4.80 ± 0.37 5.10 ± 0.24 4.60 ± 0.24 5.00 ± 0.31 4.80 ± 0.20
Diameter of left ovary (mm) 5.00 ± 0.44 5.60 ± 0.24 5.20 ± 0.20 5.50 ± 0.22 5.30 ± 0.20
Ovary organ index 0.31 ± 0.01 0.29 ± 0.02 0.28 ± 0.01 0.29 ± 0.01 0.31 ± 0.02
Values are expressed as Mean±SEM
Table 3 Effect of Rutin-I (100 mg/kg) and Rutin-II (150 mg/kg) on glucose levels measured on day 1, 21 and 36 of experiment in
Letrozole induced PCOS rats
Glucose levels (mg/dL) Control PCOS Metformin Rutin-I Rutin-II
Day 1 74.21 ± 1.93 73.23 ± 2.81 73.40 ± 3.29 73.01 ± 2.98 72.61 ± 2.42
Day 21 79.22 ± 3.21 95.61 ± 3.18a** 95.83 ± 1.93a** 93.21 ± 3.30a* 92.80 ± 2.72a*
Day 36 79.20 ± 3.11 96.44 ± 2.00a*** 77.21 ± 1.90b*** 79.80 ± 1.01b*** 76.40 ± 1.60b***
Values are expressed as Mean ± SEM
*=p< 0.05, **=p< 0.01, ***=p< 0.001
aValue vs control, bValue vs PCOS
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compared to the PCOS group. Alteration in the ovarian
enzyme activities with the treatment of Rutin (150 mg/
kg) showed statistically significant increase (P < 0.05) as
compared to PCOS group.
Letrozole increased the TBARS (P < 0.01) and
LOOH (P < 0.05) levels significantly in PCOS as com-
pared to control. Metformin did not show any signifi-
cance while rutin (100 mg/kg), rutin (150 mg/kg)
treatment exhibited significant decrease (P < 0.05) in
both antioxidants.
Effect of metformin and rutin on serum testosterone,
progesterone and estradiol values
Administration of letrozole to female rats for 36 days
resulted in a highly significant increase in the serum
testosterone as compared with the control (P < 0.001)
while the metformin, rutin-I (100 mg/kg) and rutin-II
(150 mg/kg) exhibited a moderately significant decrease
(P < 0.01) in comparison with the PCOS group but
remained non-significant when compared with the con-
trol group. There was no significant difference in the
values of estradiol among rats of all the groups. Letro-
zole administration resulted in a very significant de-
crease (P < 0.01) in the progesterone value in the PCOS
group when compared with the control group (Table 6).
Effect of metformin and rutin on lipid profile
Administration of letrozole (1 mg/kg) to female rats for
36 days resulted in a significant increase in serum TG,
VLDL-C, LDL-C and non-HDL-C, whereas HDL-C was
significantly decreased when compared with vehicle
control (P < 0.05). Metformin significantly reduced TC
(P < 0.05), LDL-C and non-HDL-C (P < 0.01). Rutin-I
(100 mg/kg) treatment caused significant reduction in
TC and non-HDL (P < 0.05). While rutin-II (150 mg/
kg) significantly lowered TC, TG, VLDL-C, LDL-C
and non-HDL-C but did not affect the level of HDL-
C (Table 7).
Effect of metformin and rutin on histopathology of ovary
The histological changes studied were as follows: (Fig. 1).
The diameter of developing follicles
The diameter of developing follicles (D20 μm –D >
600 μm) did not depict any significant difference among
the various groups.
Number of cystic and atretic follicles
The number of cystic and atretic follicles were increased
significantly (P < 0.001) in the PCOS group as compared
with the control group. Metformin, rutin (100 mg/kg)
Table 4 Effect of Rutin-I (100 mg/kg) and Rutin-II (150 mg/kg) on total protein and CRP concentration in Letrozole induced PCOS
rats after 36 days of experiment
Protein values Control PCOS Metformin Rutin-I Rutin-II
Total Protein (mg/g of tissue) 25.371 ± 1.852 40.242 ± 1.771a* 25.491 ± 2.423b* 26.701 ± 6.264 25.342 ± 2.944b*
CRP (mg/dL) 0.051 ± 0.004 0.069 ± 0.001a* 0.060 ± 0.006 0.062 ± 0.002 0.059 ± 0.004




Table 5 Effect of Rutin-I (100 mg/kg) and Rutin-II (150 mg/kg) on ROS, TBARS, LOOH, CAT, POD, SOD, GSR, GST, GSH, GSH-px
concentrations in Letrozole induced PCOS rats after 36 days of experiment
Parameters Control PCOS Metformin Rutin-I Rutin-II
ROS (U/min) 0.20 ± 0.04 0.39 ± 0.09a* 0.17 ± 0.02b* 0.19 ± 0.02b* 0.16 ± 0.01b*
TBARS (nmol/min/mg) 5.69 ± 1.07 16.06 ± 1.25a** 10.78 ± 1.07 8.93 ± 2.45b* 8.15 ± 0.82b*
LOOH (nmol/min/mg) 3.29 ± 0.48 5.39 ± 0.29a* 3.44 ± 0.47 3.59 ± 0.63 3.23 ± 0.42b*
CAT(U/min) 4.93 ± 0.08 3.49 ± 0.33a* 4.15 ± 0.47 4.22 ± 0.28 4.49 ± 0.38
POD(nmole) 12.09 ± 0.72 9.29 ± 0.01a* 10.44 ± 0.62 10.11 ± 0.58 11.87 ± 0.59b*
SOD (U/min) 5.81 ± 0.24 2.74 ± 0.29a* 5.51 ± 0.51b* 5.41 ± 1.08b* 5.72 ± 0.51b*
GSR (U/mol/mg) 3.96 ± 0.38 1.79 ± 0.09a* 3.89 ± 0.29b* 3.46 ± 0.71 4.67 ± 0.52b*
GST (U/mol/mg) 10.85 ± 0.21 8.02 ± 0.83a** 9.47 ± 0.28 9.37 ± 0.48 10.91 ± 0.22b*
GSH (U/mol/mg) 6.91 ± 0.50 4.97 ± 0.14a** 6.55 ± 0.48b* 6.39 ± 0.02b* 6.77 ± 0.88b**
GSH-px (U/mol/mg) 29.87 ± 2.14 20.35 ± 0.64a** 25.34 ± 2.11 24.24 ± 1.76 30.10 ± 1.29b**
Values are expressed as Mean ± SEM
*=p< 0.05, **=p< 0.01
aValue vs control, bValue vs PCOS
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and rutin (150 mg/kg) significantly reduced the number of
cystic follicles (P < 0.001) and atretic follicles (P < 0.05) as
compared to PCOS group (Table 8).
Number of corpus luteum
The number of corpus luteum was significantly decreased
in the PCOS group as compared to control (P < 0.001)
whereas significant recovery was shown in the metformin,
rutin-I and rutin-II groups (P < 0.05) (Table 8).
Thickness of peripheral thecal and granulosa layer in
normal and cystic follicles
The thickness of peripheral thecal layer (D200 μm -D >
600 μm) remained non-significant in the normal follicles
among the various groups but its thickness increased
significantly (P < 0.001) in the PCOS group when com-
pared with control group. The thickness was restored
significantly (P < 0.001) in metformin and rutin post
treated groups when compared with PCOS group.
PCOS group showed highly significant (P < 0.001) re-
duction in peripheral granulosa thickness in follicles when
compared with control group whereas in cystic follicles
width of granulose layer increased non-significantly in
metformin, rutin-I and rutin-II group as compare to
PCOS group (Table 9).
Discussion
Letrozole, an aromatase inhibitor, was used to induce
PCOS in the rats. Subsequently the increased weights of
rats and irregular estrous cycle in the positive control
substantiated the induction of PCOS and also signified
that the rat model is anoestrous, as it imitated anovula-
tory characteristic [33]. Treatment of PCOS induced rats
with flavonoid rutin possibly restored the estrous cyclic-
ity in rats. The rutin treated groups, however, did not
depict any significant increase in body weight which sug-
gested that rutin might have reduced the expression
levels of adipogenic genes thus reducing the weight of
adipose tissues [34].
Surprisingly, the ovarian weights, ovarian diameter and
ovarian organ index displayed no significant increase. The
non-significant anthropometrical results might be due to
the fast metabolic response of the animals, suggesting that
other genetic or environmental factors or longer time of
exposure to aromatase inhibitor was necessary to achieve
the full spectrum of ovarian pathology.
The glucose levels increased significantly when mea-
sured in the PCOS group during the day 21 and 36 of
the experiment. Letrozole seems to create a disturbance
in the hormonal profile of the animals mainly because of
increased androgen levels. This increased androgen
levels in turn induced insulin resistance hence creating a
decreased glucose tolerance [35]. Meanwhile, metformin
Table 6 Effect of Rutin-I (100 mg/kg) and Rutin-II (150 mg/kg) on serum testosterone, estradioland progesterone concentrations in
Letrozole induced PCOS rats after 36 days of experiment
Hormonal concentrations Control PCOS Metformin Rutin-I Rutin-II
Testosterone (ng/ml) 1.88 ± 0.71 10.19 ± 0.76a*** 4.51 ± 0.30 b** 5.77 ± 0.68b* 8.21 ± 1.85a**
Estradiol (ng/ml) 19.41 ± 2.21 14.26 ± 2.70 28.57 ± 4.32 34.83 ± 8.26 27.25 ± 0.48
Progesterone (pg/ml) 43.43 ± 8.81 12.76 ± 3.75a** 22.98 ± 4.85 19.66 ± 5.34a* 24.63 ± 3.46
Values are expressed as Mean ± SEM
*=p< 0.05, **=p< 0.01, ***=p< 0.001
aValue vs control, bValue vs PCOS
Table 7 Effect of Rutin-I (100 mg/kg) and Rutin-II (150 mg/kg) on total cholesterol, triglycerides, HDL- C, LDL-C, VLDL-C, Non-HDL-C,
TC/HDL, TG/HDL and LDL/HDL concentrations in Letrozole induced PCOS rats after 36 days of experiment
Parameters Control PCOS Metformin Rutin-I Rutin-II
Total Cholesterol(mg/dL) 215.60 ± 3.43 231.10 ± 4.27 211.30 ± 6.81b* 212.21 ± 1.53b* 207.10 ± 2.24b**
Triglycerides (mg/dL) 185.11 ± 4.23 213.10 ± 5.16a* 197.40 ± 5.82 199.20 ± 6.93 186.12 ± 4.62b*
HDL-C (mg/dL) 160.70 ± 4.17 144.41 ± 3.63a* 153.21 ± 1.80 146.43 ± 4.52 159.80 ± 3.14b*
LDL-C (mg/dL) 17.83 ± 3.98 42.99 ± 1.99a** 18.58 ± 7.22b** 25.81 ± 5.11 10.05 ± 2.29b***
VLDL-C (mg/dL) 37.03 ± 0.85 42.61 ± 1.03a* 39.49 ± 1.16 39.83 ± 1.39 37.20 ± 0.92b*
Non-HDL-C(mg/dL) 54.86 ± 4.48 85.61 ± 1.50a** 58.07 ± 7.32b** 65.65 ± 4.75b* 47.24 ± 2.64b***
TC/HDL 1.34 ± 0.03 1.59 ± 0.02a*** 1.38 ± 0.05b** 1.45 ± 0.04 1.29 ± 0.02b***c*
TG/HDL 1.16 ± 0.04 1.48 ± 0.06a** 1.29 ± 0.03 1.37 ± 0.06 1.17 ± 0.04b**
LDL/HDL 0.11 ± 0.03 0.29 ± 0.01a** 0.12 ± 0.05b** 0.18 ± 0.04 0.06 ± 0.02b***
Values are expressed as Mean ± SEM
* = p < 0.05, ** = p < 0.01, *** = p < 0.001
a Value vs control, b Value vs PCOS, c Value vs Metformin
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reduced the glucose levels significantly as compared to
PCOS group. This may be due to the fact that metfor-
min treatment decreased the glucose resistance by main-
taining the glucose homeostasis and also by improving
the insulin-mediated uptake of glucose [35, 36]. Rutin
flavonoid significantly reduces the glucose values in the
treated groups as compared with PCOS group because
of its antihyperglycemic effect and caused a decrease in
the glycaemic levels by conceivably playing its role as
potentiating the insulin secretion by the β-cells of Islets
of Langerhans thus promoting a balanced uptake of glu-
cose by the cells [37]. It also suggested that rutin might
be a potential agent for glycaemic control through en-
hancement of insulin-dependent receptor kinase activity,
thus inducing the insulin signalling pathway, and conse-
quently causing increased glucose transporter 4 trans-
location and increased glucose uptake [38].
The total protein index increased significantly in the
PCOS group. This abnormal level of total protein might
suggest infectious and chronic inflammation in the
PCOS group which might be due to the abnormal an-
drogen secretions. However, metformin significantly
lowered the amount of total protein as compared with
the positive vehicle group. The improved sensitivity of
proteins and protein hormones after the metformin ther-
apy down regulate the increased circulating levels of
protein in the blood [39]. Rutin flavonoid significantly
decreased the total protein level by inhibiting the eicosa-
noids and cytokines due to its pharmacologic actions
[40]. The C- reactive protein (CRP) is an acute phase
protein and a very expedient indicator of inflammation
in a tissue. In present study, the CRP levels increased
significantly in the PCOS group thus exhibiting severe
infection [41].
Elevated testosterone levels in PCOS most probably re-
flect build-up of androgens because conversion of andro-
gen substrates into estrogens was blocked by aromatase
inhibitor. The decrease in testosterone concentration in
metformin group reflect diminished androgen biosyn-
thesis by the ovary [42]. The diminution of estrogen pro-
duction by aromatase inhibition can cause enhanced
secretion of LH in hypothalamus and pituitary most likely
by negative feedback of estrogens.
Oxidative stress is generally regarded as the phenom-
ena where the generation of reactive oxygen species
Fig. 1 Histopathological features of ovary in Letrozole induced PCOS
in rats. Representative photographs of section of ovary showing various
developing follicles, cystic follicle (c.f), atretic follicle (a.f) and corpus
luteum (c.l): (a) Control group (b) PCOS group (c) Metformin group (d)
Rutin-I (100 mg/kg) and (e) Rutin-II (150 mg/kg) (40× magnification)
Table 8 Effect of Rutin-I (100 mg/kg) and Rutin-II (150 mg/kg) on number of cystic follicles, atretic follicles and corpus luteum in
Letrozole induced PCOS rats after 36 days of experiment
Number of follicles Control PCOS Metformin Rutin-I Rutin-II
Cystic follicles 0.0 ± 0.0 10.17 ± 0.70a*** 5.16 ± 0.30a***b*** 6.16 ± 0.47 a***b*** 7.33 ± 0.42a***b**c*
Atreticfollicles 2.00 ± 0.25 4.50 ± 0.34a*** 2.83 ± 0.47b* 2.66 ± 0.33b* 2.83 ± 0.40b*
Corpousluteum 6.80 ± 0.37 2.40 ± 0.24a*** 4.20 ± 0.58a**b* 2.40 ± 0.50a***c* 4.40 ± 0.24a**b*d*
Values are expressed as Mean ± SEM
*p< 0.05, **p< 0.01, ***p< 0.001
aValue vs control, bValue vs PCOS, cValue vs Metformin, dValue vsRutin-I
Table 9 Effect of Rutin-I (100 mg/kg) and Rutin-II (150 mg/kg)
on thickness of thecal layer and peripheral granulosa layer in
Letrozole induced PCOS rats after 36 days of experiment
Thickness (μm) Rutin I Control Rutin II PCOS Metformin
Thecal Layer – 27.56±2.10 21.25±3.09
18.11±1.28a*** 16.78±1.25a***
Granulosa Layer – 22.00±2.55 30.00±2.73
26.00±2.91 25.00±3.16
Values are expressed as Mean ± SEM
***=p< 0.001
aValue vs PCOS
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(ROS) cause disruption in the normal functionality of
biological system. The aerobic cells have a counter
mechanism to deal with oxidative stress by trapping the
reactive oxygen intermediates but the inequity in terms
of the rate of the production of ROS and their protective
systems can cause oxidative stress over time. In present
study, the ROS level increased significantly in the PCOS
group which depicted an increase in the oxidative stress
[43]. The increase in ROS level indicates the molecular
damage in the cellular structure and the tissue was
mainly due to the over production of free oxidative radi-
cals. ROS value was also decreased significantly in the
rutin groups, which is due to the antioxidant activity of
rutin. The exact mechanism through which rutin in-
duces antioxidative action is not clear but it reduces the
causative agents of oxidative stress [44].
Lipid peroxidation is a free-radical mediated promul-
gation of oxidative offence inserted to polyunsaturated
fatty acids involving numerous types of free radicals.
The cessation of lipid peroxidation occurs by antioxi-
dants through their enzymatic action or by free radical
scavenging activity [45]. The increase in the lipid per hy-
droxide levels might be due to the termination of anti-
oxidant effect which caused pathogenesis of the disease.
Histopathological observation of ovaries taken from
Letrozole treated animals displayed remarkable resem-
blance to human PCOS, revealing sub capsular cysts
lined with a thin layer of granulosa cells and hyperplasia
of theca cells [12]. It has been observed that the in-
creased levels of intra-ovarian androgens lead to abnor-
mal follicular growth and an increase in follicular artesia
[46, 47]. Number of corpus luteum and different devel-
oping follicles measuring in diameter from 20 μm to
more than 600 μm also decreased non-significantly in
PCOS group. Cystic follicles were much larger in size as
compared to other follicles of ovary with a clear antrum
but lacked oocyte. Thickness of peripheral granulosa layer
was decreased while that of theca layer was increased
significantly in different follicles of PCOS group, as com-
pared to control group. Contrary to this, post treated
groups exhibited non-significant increase when compared
with PCOS group. These histological findings were pin-
pointing towards the existence of biologically active levels
of FSH, increased LH, and lack of interplay between
granulosa and theca cells, which would otherwise lead to
ovulation, in the PCOS group.
Conclusions
Concluding our work, present study demonstrates anti-
androgenic properties of rutin. It showed estrogenic,
antiandrogenic and anti hyperglycemic effects and re-
covered ovarian cysts and its protective properties was
seen to be comparable to that of metformin. The restor-
ation of ovarian function and hormonal profile by rutin
treatment could be supportive in managing PCOS. Out-
comes of the study also revealed that letrozole induced
PCOS had an enhanced level of oxidative stress along
with hyperglycemia and hyperlipidemia. Oxidative stress
in turn damaged the tissue by reactive oxygen species
(ROS) and the rutin flavonoid was able to antidote the
oxidative stress. Meanwhile, rutin also played an impera-
tive role in reducing the oxidative stress, boosting the
antioxidant status, and possibly reducing the ROS and
lipid peroxidation. It displayed a significant role in subsid-
ing the hyperlipidemic state and hyperglycemic state and it
can be used as a possible ameliorative medication for cur-
ing clinical and biochemical characteristics of polycystic
ovary syndrome, its properties were analogous to that of
standard metformin. Further research is prerequisite to in-
vestigate the pharmacologic and therapeutic potentials of
rutin so that it can be used as an adjunct therapy sideways
to currently used drugs in PCOS management.
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